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Fenoﬁbrate, a ﬁbric acid derivative, is used to treat diabetic dyslipidemia, hypertriglyceridemia, and combined hyperlipidemia,
administeredaloneorincombinationwithstatins.Rhabdomyolysisisdeﬁnedasapathologicalconditioninvolvingskeletalmuscle
cell damage leading to the release of toxic intracellular material into circulation. Its major causes include muscle compression or
overexertion; trauma; ischemia; toxins; cocaine, alcohol, and drug use; metabolic disorders; infections. However, rhabdomyolysis
associated with fenoﬁbrate is extremely rare. Herein we report a 45-year-old female patient who was referred to our department
becauseofgeneralizedmusclepain,fatigue,weakness,andoliguriaoverthepreceding3weeks.Onthebasisofthepathogenesisand
clinicalandlaboratoryexaminations,adiagnosisofacuterenalfailuresecondarytofenoﬁbrate-inducedrhabdomyolysiswasmade.
Weekly followups for patients who are administered fenoﬁbrate are the most important way to prevent possible complications.
1.Introduction
Rhabdomyolysis is a clinical and biochemical syndrome
resulting from skeletal muscle injury and the consequent
release of muscle cell constituents into circulation. It may
result in myoglobinuria, the ﬁltration of myoglobin into
the urine, and is often associated with acute renal failure
(ARF) [1]. Its major causes include muscle compression or
overexertion; ischemia; toxins; metabolic disorders; cocaine
[2], alcohol [2], and drug use; infections [3]. However, drug-
inducedrhabdomyolysisoccursrarely.Innearlyallpresented
cases, a predisposing factor for rhabdomyolysis, such as high
statin dose, diabetes, older age, female gender, renal disease,
or hypothyroidism, is present [4, 5]. Herein, we report a 45-
year-old diabetic female patient without any known prior
renal disease who presented with acute renal failure that
developed after fenoﬁbrate treatment.
2.CaseReport
A 45-year-old female patient presented to our hospital with
complaints of muscle pain, weakness, fatigue, decreased
urine outﬂow, and a dark brown urine color for the previous
3 weeks. She had a long history of type 2 diabetes and
had had hypertriglyceridemia for about 2 years, which was
treated with glimepiride (3mg daily) and metformin (2
1-g tablets daily) . About 3 weeks before presentation,
she was prescribed fenoﬁbrate 200mg daily for hyper-
triglyceridemia, and she had used it regularly. Her history
included diabetic hypertension treated uneventfully with
perindopril for 2 years. She had no family history of liver,
muscle, or kidney disease, had not traveled recently, and
was sexually stable with no history of alcohol, tobacco, or
drug abuse. Decreased urine output and generalized weak-
ness (3/5, muscle strength) and muscular tenderness were
detected on clinical examination. Laboratory investigations
revealed the following levels: serum creatine kinase (CK):
5698U/L;AST:179U/L;ALT:191U/L;creatinine:2.2mg/dL;
urea: 150mg/dL; LDH: 974U/L; fasting glucose: 190mg/dL;
HbA1C: 7.85%; triglyceride: 177mg/dL; total cholesterol:
164mg/dL; myoglobulin: >100,000mcg/ml. Her liver and
renal functions tests were normal before the fenoﬁbrate
therapy. She had no recent viral illness, history of trauma,
epilepsy, hypothyroidism, or over-the-counter medication2 Case Reports in Medicine
Table 1: Results of our patient’s initial, second day, and last day laboratory tests.
Serum Initial day Second day Third day Reference range
Urea (mg/dL) 29.5 20.3 12.2 10–45
Creatinine (mg/dL) 2.2 1.4 1.1 0.5–1.14
ALT (U/L) 9.7 18.3 31.3 10–35
AST (U/L) 27.6 25.2 24.2 10–40
CK (U/L) 7.8 28.7 19.9 38–174
LDH (U/L) 31.8 23.11 17.10 125–243
Na (mmol/L) 18.5 22.5 19.5 136–145
Ca (mg/dL) 8.0 8.4 8.9 8.4–10.2
K (mmol/L) 3.9 3.6 3.8 3.5–5.1
P (mg/dL) 3.4 2.6 2.3 2.7–4.5
Table 2: A summary of reported ﬁfteen cases of rhabdomyolysis associated with fenoﬁbrate therapy.
References Year Age Sex Medical History Other drug Fenoﬁbrate BUN Cr CK
1W u e t a l . [ 6] 2009 52 F DL 200mg, for 1mo 43.8
2D e S o u z a e t a l . [ 7] 2009 54 M CRF, DL, HT, Hypothyroidism 200mg, for 2mo 120 4.9 52749
3C ¸etinkaya et al. [5] 2008 60 F DM-II, HT, DL 200mg, for NA 4.2 11867
4 Unal et al. [1] 2008 56 F CAD, DL Pravastatin 200mg, for 2mo 37 2.6 97392
58 M CABG, DL Atorvastatin 200mg, for 1mo 36 3.6 96639
5 Yildiz et al. [8] 2008 74 M CABG, HT, DL 267mg, for 2wk 224 5.3 26680
6T a h m a z e t a l . [ 9] 2007 42 F HT, DL 250mg, for 4wk 90 5.5 21000
7 Dedhia and Munsi [10] 2007 68 M CABGx2, HT, DL Rosuvastatin 160mg, for 3wk 2.3 23665
8J a c o b e t a l . [ 11] 2005 70 M DM-II, HT, DL, Hypothyroidism Simvastatin 160mg, for 4wk 2.7 10936
9I r e l a n d e t a l . [ 12] 2005 67 F HT, DL Rosuvastatin 160mg, for 2wk 58 3.6 13808
10 Kursat et al. [13] 2005 63 F HT, DL, Hypothyroidism Simvastatin 200mg, for 4wk 188 4.5 8842
11 Ghosh et al. [14] 2004 58 M CAD, DL 200mg, for 5wk 1129
12 Barker et al. [15] 2003 56 F HT, DM-II, DL 200mg, for 10d 2 5632
13 Clouatre et al. [16] 1999 57 F CRF, DL, HT, Hypothyroidism 200mg, for 4wk 8850
55 F CRF, PCRD, DL, Hypothyroidism Simvastatin 200mg, for 3wk 11360
BUN: blood urea nitrogen (mg/dl), Cr: creatinine (mg/dl), DM: diabetes mellitus, CRF: chronic renal failure, CK: serum creatine kinase (IU/L), HT:
hypertension, DL: dyslipidemia, CAD: coronary artery disease, CABG: coronary artery by-pass graft, and PCRD: polycystic renal disease.
use and had not taken any other medication known to
induce rhabdomyolysis. The fenoﬁbrate was discontinued,
and intravenous ﬂuid replacement with bicarbonate ther-
apy was started. The myalgia resolved, urine output was
normalized, and serum urea and creatinine decreased to
normal values on the second day of treatment. The initial,
second, and last day laboratory results are presented in
Table 1.
3. Discussion
Fenoﬁbrate is a derivative of ﬁbric acid. It reduces very
low-density lipoprotein (VLDL) and low-density lipoprotein
(LDL) and increases high-density lipoprotein (HDL). The
side eﬀects of ﬁbrate treatment include gastrointestinal com-
plaints, gallstones, skin reactions, and blood disturbances
that are tolerable and reversible. The most important side
eﬀect of fenoﬁbrate is rhabdomyolysis [1, 5]. Rhabdomyol-
ysis is a syndrome characterized by muscle necrosis and the
release of intracellular muscle contents into systemic circu-
lation. Oliguric or nonoliguric ARF is the most common
complication of rhabdomyolysis, occurring in 10%–40% of
patients [17].
We established a diagnosis of ARF, which was probably
due to fenoﬁbrate-induced rhabdomyolysis based on ele-
vated CK and the absence of any other risk factor related to
rhabdomyolysis and ARF according to the Naranjo probabil-
ity scale [18]. The demographics, medical history, and per-
sonal history of this patient did not suggest any underlying
disease that may have caused the rhabdomyolysis; however,
the time sequence of the start of the fenoﬁbrate and onset of
the ARF were consistent with drug-related rhabdomyolysis-
related renal injury. Although no rechallenge was attempted,
the rapid improvement in muscular enzyme levels and renal
function after discontinuation of fenoﬁbrate suggests an
association with ARF and rhabdomyolysis related to the use
of the drug. Other causes for muscular and/or renal injury
(e.g., viruses, toxic exposures, or diabetes mellitus) were
possible but not suggested by the clinical history. In our case,
rapidly diminishing enzymes on the third day after stoppingCase Reports in Medicine 3
the fenoﬁbrate therapy indicated that the current clinical
situation was associated with fenoﬁbrate.
Acute renal failure secondary to fenoﬁbrate monother-
apy-inducedrhabdomyolysisisarareandnewlyencountered
clinical condition, and there are only sixteen cases associated
with fenoﬁbrate therapy (nine with monotherapy and seven
with fenoﬁbrate-statin combination therapy) which have
been published in the English-language literature. Fifteen
of them are summarized in Table 2 [1, 4–16]. The risk for
serious muscle toxicity appears to be increased in elderly
patientsandinpatientswithdiabetes[5,11,15], renal failure
[4, 7, 16], or hypothyroidism [4, 5, 7, 11, 13, 15, 16]. For
the patient we present here, tests done 2 months previously
found normal results for renal function, thyroid function,
and anti-TPO antibody levels. The only risk factor she had
was type 2 diabetes mellitus.
C ¸etinkaya et al. [5] indicated that dehydration can be an
additive risk factor in elderly patients who use fenoﬁbrate;
thus, patients in this group should be carefully informed
about possible side eﬀects and should be followed closely
during the therapy. The patient presented here did not come
to any of the controls afterstarting the therapy, and when she
ﬁnally came, she had moderate dehydration.
Inconclusion,prescribersandusersoffenoﬁbrateshould
be alert to the possibility of its potentially fatal side eﬀects
such as rhabdomyolysis and related ARF. Screening for
risk factors such as hepatic impairment, renal insuﬃciency,
serious infections, hypothyroidism, and diabetes should
also be considered, especially in elderly patients who are
treated with fenoﬁbrate. Doctors who work in regions in
which doctor-patient relationships are poor should exercise
particular caution when prescribing such drugs.
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